[1] Raghu G,Collard HR,Egan J,et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and anagement[J]. Am J Respir Crit Care Med,2011,183:788-824.
[2] 蔡后荣.2011年特发性肺间质纤维化诊断和治疗循证新指南解读[J]. 中国呼吸与危重监护杂志,2011,10(4):313-316.
[3] Watter LC,King TE,Schw arz MI,et al.A clinical,Radiographic,and Physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis[J].Am Rev Respir Dis,1986,133:97.
[4] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:14-65.
[5] 田德禄. 中医内科学[M]. 北京:人民卫生出版社,2003:368-378.
[6] 张心月,贾新华,王立娟,等.从气血变化看肺间质纤维化[J]. 中医药学报,2012,40(3):56-57.
[7] 樊茂蓉,张燕萍,苗青,等.肺间质纤维化的中医发病机制与治则探讨[J]. 中医杂志,2012,53(3):203-204.
[8] 杨景青,张伟.论叶氏“络病理论”治疗肺间质纤维化[J]. 辽宁中医药大学学报,2013,15(3):118-119.
[9] Jones PW,Quirk FH,Baveystock CM. The St Georg's Respiratory Questionnaire[J]. Respir Med,1991,85(Suppl B):25-31.
[10] American Thoracic Society/European Respiratory Society.American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med,2002,165(2):277-304.
[11] 中华医学会呼吸病学分会. 特发性肺(间质)纤维化诊断和治疗指南(草案)[J]. 中华结核和呼吸杂志,2002,25(7):387-389.
[12] Raghu G,Weycker D,Edelsberg J,et al. Incidence and prevalence of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med,2006,174:810-816.
[13] Paul W. Noble,Carlo Albera,Williamson Z,et al. Pirfenidone for idiopathic pulmonary fibrosis:analysis of pooled data from three multinational phase 3 trials[J]. Eur Respir J,2016,47:243-253.
[14] Tamera Cortel,Francesco Bonella,Bruno Crestani,et al. Safety,tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Corte et al[J]. Respiratory Research,2015,16:116-126.
[15] 罗莉莎.槲皮素抗纤维化作用机制研究进展[J]. 国外医学:中医中药分册,2005,27(6):330-332.
[1]曹芳,吴志松,付小芳,等.肺痹汤治疗特发性肺间质纤维化咳嗽22例[J].环球中医药,2015,8(01):87.[doi:10.3969/j.issn.1674-1749.2015.01.023]